Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Liam, Chong KinChong KinLiamAhmad, Azura RozilaAzura RozilaAhmadHsia, Te-ChunTe-ChunHsiaZhou, JianyingJianyingZhouKim, Dong-WanDong-WanKimSoo, Ross AndrewRoss AndrewSooCheng, YingYingChengLu, ShunShunLuShin, Sang WonSang WonShinCHIH-HSIN YANGZhang, YipingYipingZhangZhao, JunJunZhaoBerghoff, KarinKarinBerghoffBruns, RolfRolfBrunsJohne, AndreasAndreasJohneWu, Yi-LongYi-LongWu2023-08-212023-08-212023-05-1510780432https://scholars.lib.ntu.edu.tw/handle/123456789/634649The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant NSCLC (data cut-off: September 3, 2021).enRandomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysisjournal article10.1158/1078-0432.CCR-22-3318369717772-s2.0-85159735583https://api.elsevier.com/content/abstract/scopus_id/85159735583